---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-002008"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T06:51:00.518502+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silexion SIL204 shows ~90% inhibition in colorectal cells; expands to lung & pancreatic

## Summary
- SIL204 inhibited GP2D colorectal cancer cells with ~90% inhibition rate in preclinical study.
- Dose-dependent reduction observed in Panc-1 (pancreatic), A427 (lung) cell lines at nanomolar concentrations.
- Company to conduct additional lung (NSCLC) cancer cell line study in coming weeks.
- KRAS G12D mutation targeted; addresses pancreatic (~90%), colorectal (~45%), and lung (~35%) cancers.
- Ilan Hadar cites SIL204's enhanced lipid-conjugate delivery enabling potent activity at low doses.

## SEC filing metadata
- accession: 0001178913-25-002008
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002008/0001178913-25-002008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002008/zk2533298.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-002008
- JSON: https://secwatch.observer/filing/0001178913-25-002008.json
- Plain text: https://secwatch.observer/filing/0001178913-25-002008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.